Zentalis to cut 40% of workforce, focus on azenosertib

Stock Information for Zentalis Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.